The 3,600 sqft facility will help develop the MIMIX sustained-release intradermal microneedle patch, which is planned for proof-of-concept trials for COVID-19 in 2022
Attendees from Lonza, the NHS, ITH Pharma, Guardtech, AstraZeneca, Kingspan and more, have attended a two day event in Birmingham for the cleanroom and contamination control...
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.